BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 18029909)

  • 1. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration.
    Li YT; Swales KE; Thomas GJ; Warner TD; Bishop-Bailey D
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2606-11. PubMed ID: 18029909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiatherosclerotic effect of farnesoid X receptor.
    Mencarelli A; Renga B; Distrutti E; Fiorucci S
    Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H272-81. PubMed ID: 19028791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
    Pineda Torra I; Claudel T; Duval C; Kosykh V; Fruchart JC; Staels B
    Mol Endocrinol; 2003 Feb; 17(2):259-72. PubMed ID: 12554753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells.
    Zhang Q; He F; Kuruba R; Gao X; Wilson A; Li J; Billiar TR; Pitt BR; Xie W; Li S
    Cardiovasc Res; 2008 Feb; 77(3):560-9. PubMed ID: 18006431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and activation of the farnesoid X receptor in the vasculature.
    Bishop-Bailey D; Walsh DT; Warner TD
    Proc Natl Acad Sci U S A; 2004 Mar; 101(10):3668-73. PubMed ID: 14990788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.
    Martínez-Fernández P; Hierro L; Jara P; Alvarez L
    Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1119-29. PubMed ID: 19228886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response.
    Wang YD; Chen WD; Wang M; Yu D; Forman BM; Huang W
    Hepatology; 2008 Nov; 48(5):1632-43. PubMed ID: 18972444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis.
    Fiorucci S; Rizzo G; Antonelli E; Renga B; Mencarelli A; Riccardi L; Morelli A; Pruzanski M; Pellicciari R
    J Pharmacol Exp Ther; 2005 Oct; 315(1):58-68. PubMed ID: 15980055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression.
    Swales KE; Korbonits M; Carpenter R; Walsh DT; Warner TD; Bishop-Bailey D
    Cancer Res; 2006 Oct; 66(20):10120-6. PubMed ID: 17047076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis.
    Fiorucci S; Clerici C; Antonelli E; Orlandi S; Goodwin B; Sadeghpour BM; Sabatino G; Russo G; Castellani D; Willson TM; Pruzanski M; Pellicciari R; Morelli A
    J Pharmacol Exp Ther; 2005 May; 313(2):604-12. PubMed ID: 15644430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic stimulation of farnesoid X receptor impairs nitric oxide sensitivity of vascular smooth muscle.
    Kida T; Murata T; Hori M; Ozaki H
    Am J Physiol Heart Circ Physiol; 2009 Jan; 296(1):H195-201. PubMed ID: 19011043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chenodeoxycholic acid-mediated activation of the farnesoid X receptor negatively regulates hydroxysteroid sulfotransferase.
    Miyata M; Matsuda Y; Tsuchiya H; Kitada H; Akase T; Shimada M; Nagata K; Gonzalez FJ; Yamazoe Y
    Drug Metab Pharmacokinet; 2006 Aug; 21(4):315-23. PubMed ID: 16946559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo.
    Rizzo G; Disante M; Mencarelli A; Renga B; Gioiello A; Pellicciari R; Fiorucci S
    Mol Pharmacol; 2006 Oct; 70(4):1164-73. PubMed ID: 16778009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor-gamma ligands inhibit nitric oxide synthesis in vascular smooth muscle cells.
    Ikeda U; Shimpo M; Murakami Y; Shimada K
    Hypertension; 2000 Jun; 35(6):1232-6. PubMed ID: 10856269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bile acid signaling through FXR induces intracellular adhesion molecule-1 expression in mouse liver and human hepatocytes.
    Qin P; Borges-Marcucci LA; Evans MJ; Harnish DC
    Am J Physiol Gastrointest Liver Physiol; 2005 Aug; 289(2):G267-73. PubMed ID: 15817812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farnesoid X Receptor and Its Ligands Inhibit the Function of Platelets.
    Moraes LA; Unsworth AJ; Vaiyapuri S; Ali MS; Sasikumar P; Sage T; Flora GD; Bye AP; Kriek N; Dorchies E; Molendi-Coste O; Dombrowicz D; Staels B; Bishop-Bailey D; Gibbins JM
    Arterioscler Thromb Vasc Biol; 2016 Dec; 36(12):2324-2333. PubMed ID: 27758768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bile acid receptor FXR is a modulator of intestinal innate immunity.
    Vavassori P; Mencarelli A; Renga B; Distrutti E; Fiorucci S
    J Immunol; 2009 Nov; 183(10):6251-61. PubMed ID: 19864602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The nuclear bile acid receptor FXR is activated by PGC-1alpha in a ligand-dependent manner.
    Kanaya E; Shiraki T; Jingami H
    Biochem J; 2004 Sep; 382(Pt 3):913-21. PubMed ID: 15202934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The farnesoid X receptor induces very low density lipoprotein receptor gene expression.
    Sirvent A; Claudel T; Martin G; Brozek J; Kosykh V; Darteil R; Hum DW; Fruchart JC; Staels B
    FEBS Lett; 2004 May; 566(1-3):173-7. PubMed ID: 15147890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity.
    Gineste R; Sirvent A; Paumelle R; Helleboid S; Aquilina A; Darteil R; Hum DW; Fruchart JC; Staels B
    Mol Endocrinol; 2008 Nov; 22(11):2433-47. PubMed ID: 18755856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.